Pharmacotherapy of high-risk population for developing psychosis

por Mohr, P.
Publicado 2023

Experiences and projections for the future of research, training and other academic activities: Will it be the same?

por Mohr, P.
Publicado 2021

Antipsychotics for elderly with psychosis: Deprescribe or continue?

por Mohr, P.
Publicado 2021

Impact of the Pandemic on Psychiatric Research and Publications

por Mohr, P.
Publicado 2022

Treating Catatonia: a Blind Spot of Psychiatry?

por Mohr, P.
Publicado 2022

The s-process branching at $^{186}Re$ revised

por Mohr, P, Goriely, S, Shizuma, T, Hayakawa, T
Publicado 2006

Relativistic, Quantum Electrodynamic and Weak Interaction Effects in Atoms Meeting

por Johnson, Walter, Mohr, P J, Sucher, Joseph
Publicado 1989

Staging of cutaneous melanoma

por Mohr, P., Eggermont, A. M. M., Hauschild, A., Buzaid, A.
Publicado 2009

The (n, $\gamma$) cross sections of short-living s-process branching points

por Sonnabend, Kerstin, Mengoni, A., Mohr, P., Rauscher, T., Vogt, K., Zilges, A.
Publicado 2004

Increase in prevalence of current mental disorders in the context of COVID-19: analysis of repeated nationwide cross-sectional surveys

por Winkler, P., Formanek, T., Mlada, K., Kagstrom, A., Mohrova, Z., Mohr, P., Csemy, L.
Publicado 2020

Serum progesterone and prognosis in operable breast cancer.

por Mohr, P. E., Wang, D. Y., Gregory, W. M., Richards, M. A., Fentiman, I. S.
Publicado 1996

Biomarkers in melanoma

por Gogas, H., Eggermont, A. M. M., Hauschild, A., Hersey, P., Mohr, P., Schadendorf, D., Spatz, A., Dummer, R.
Publicado 2009

Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

por Hauschild, A, Garbe, C, Stolz, W, Ellwanger, U, Seiter, S, Dummer, R, Ugurel, S, Sebastian, G, Nashan, D, Linse, R, Achtelik, W, Mohr, P, Kaufmann, R, Fey, M, Ulrich, J, Tilgen, W
Publicado 2001

A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma(☆)

por Tarhini, A.A., Toor, K., Chan, K., McDermott, D.F., Mohr, P., Larkin, J., Hodi, F.S., Lee, C.-H., Rizzo, J.I., Johnson, H., Moshyk, A., Rao, S., Kotapati, S., Atkins, M.B.
Publicado 2021

Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study

por Stege, H. M., Haist, M., Schultheis, S., Fleischer, M. I., Mohr, P., Ugurel, S., Terheyden, P., Thiem, A., Kiecker, F., Leiter, U., Becker, J. C., Meissner, M., Kleeman, J., Pföhler, C., Hassel, J., Grabbe, S., Loquai, C.
Publicado 2021

Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety

por Malvehy, J, Hauschild, A, Curiel-Lewandrowski, C, Mohr, P, Hofmann-Wellenhof, R, Motley, R, Berking, C, Grossman, D, Paoli, J, Loquai, C, Olah, J, Reinhold, U, Wenger, H, Dirschka, T, Davis, S, Henderson, C, Rabinovitz, H, Welzel, J, Schadendorf, D, Birgersson, U
Publicado 2014

A randomised, phase II study of intetumumab, an anti-α(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma

por O'Day, S, Pavlick, A, Loquai, C, Lawson, D, Gutzmer, R, Richards, J, Schadendorf, D, Thompson, J A, Gonzalez, R, Trefzer, U, Mohr, P, Ottensmeier, C, Chao, D, Zhong, B, de Boer, C J, Uhlar, C, Marshall, D, Gore, M E, Lang, Z, Hait, W, Ho, P
Publicado 2011

New measurement of the cross section of the big bang nucleosynthesis reaction $D(\alpha, \gamma)^{6}Li$ and its astrophysical impact

por Hammache, F, Galaviz, D, Sümmerer, K, Typel, S, Uhlig, F, Coc, A, Attallah, F, Caamano, M, Cortina-Gil, D, Geissel, H, Hellström, M, Iwasa, N, Kiener, J, Koczón, P, Kohlmeyer, B, Mohr, P, Schümann, F, Schwab, E, Schwarz, K, Senger, P, Sorlin, O, Tatischeff, V, Thibaud, J P, Wagner, A, Walus, A
Publicado 2006

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

por Long, G. V., Flaherty, K. T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J. B. A. G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M. A., Lane, S. R., Legos, J. J., Mookerjee, B., Grob, J.-J.
Publicado 2017

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

por Long, G V, Flaherty, K T, Stroyakovskiy, D, Gogas, H, Levchenko, E, de Braud, F, Larkin, J, Garbe, C, Jouary, T, Hauschild, A, Chiarion-Sileni, V, Lebbe, C, Mandalá, M, Millward, M, Arance, A, Bondarenko, I, Haanen, J B A G, Hansson, J, Utikal, J, Ferraresi, V, Mohr, P, Probachai, V, Schadendorf, D, Nathan, P, Robert, C, Ribas, A, Davies, M A, Lane, S R, Legos, J J, Mookerjee, B, Grob, J -J
Publicado 2019